Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Investigation of Pathomechanisms, Prevention and Treatment of Non-Antibody Dependent Murine Transfusion Related Acute Lung Injury
FY 2015-16
Summary
Canadians and society at large enjoy access to medical care which can be lifesaving. A key component of our ability to resuscitate or revive badly injured or ill patients revolves around transfusion of blood products. Though blood products offer incredible capacity to benefit patients in need, they are not without risk. After the Krever inquiry of 1993 in Canada pertaining to the "tainted blood scandal" our blood supply is now very safe as far as the risk of contracting infectious diseases from blood. Though infrequent, in around 1 in 5000 transfusions, the most lethal and thus serious risk remaining is transfusion related acute lung injury (TRALI). TRALI is a serious lung injury as affected patients have more than a 10% chance of dying. TRALI can involve antibodies or other bioactive components from donor blood which leads to changes in recipient lung function after transfusion. Antibody-mediated TRALI rates have been falling since special interventions to reduce the amounts of antibodies in donated blood have been initiated. Other bioactive TRALI causing components in donated blood are more elusive and harder to identify, let alone eliminate. We address these issues directly with the proposed project which identifies and devises strategies to control or eliminate non-antibody mediated TRALI. To accomplish this goal we have developed a novel mouse model simulating critically ill humans receiving platelet transfusions as epidemiology studies have shown these patients and blood products to be associated with high risks of TRALI. Our mouse model allows an efficient and novel way to study TRALI by investigating its mechanisms of action with the ultimate goal of predicting TRALI cases and allowing for prevention and or treatment of TRALI. As such, this project addresses the knowledge gap for treating and preventing TRALI given that at present there are no available focused treatments for TRALI beyond supportive care.
Department
Program
Doctoral: Vanier Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
339767
Name
McVey Mark J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Investigation of Pathomechanisms, Prevention and Treatment of Non-Antibody Dependent Murine Transfusion Related Acute Lung Injury
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Extracellular Vesicles; Non-Antibody Mediated Mechanisms; Platelets; Sphingolipids; Storage Of Blood Products; Transfusion Related Acute Lung Injury
Abstract
Canadians and society at large enjoy access to medical care which can be lifesaving. A key component of our ability to resuscitate or revive badly injured or ill patients revolves around transfusion of blood products. Though blood products offer incredible capacity to benefit patients in need, they are not without risk. After the Krever inquiry of 1993 in Canada pertaining to the "tainted blood scandal" our blood supply is now very safe as far as the risk of contracting infectious diseases from blood. Though infrequent, in around 1 in 5000 transfusions, the most lethal and thus serious risk remaining is transfusion related acute lung injury (TRALI). TRALI is a serious lung injury as affected patients have more than a 10% chance of dying. TRALI can involve antibodies or other bioactive components from donor blood which leads to changes in recipient lung function after transfusion. Antibody-mediated TRALI rates have been falling since special interventions to reduce the amounts of antibodies in donated blood have been initiated. Other bioactive TRALI causing components in donated blood are more elusive and harder to identify, let alone eliminate. We address these issues directly with the proposed project which identifies and devises strategies to control or eliminate non-antibody mediated TRALI. To accomplish this goal we have developed a novel mouse model simulating critically ill humans receiving platelet transfusions as epidemiology studies have shown these patients and blood products to be associated with high risks of TRALI. Our mouse model allows an efficient and novel way to study TRALI by investigating its mechanisms of action with the ultimate goal of predicting TRALI cases and allowing for prevention and or treatment of TRALI. As such, this project addresses the knowledge gap for treating and preventing TRALI given that at present there are no available focused treatments for TRALI beyond supportive care.
Competitiondate
201511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
McVey, Mark J
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~